

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 April 2022 (21.04.2022)



(10) International Publication Number
WO 2022/081095 A1

(51) International Patent Classification:

A61K 31/455 (2006.01) *A61P 25/02* (2006.01)
A61P 17/06 (2006.01) *A61P 29/00* (2006.01)
A61P 19/00 (2006.01) *A61P 37/00* (2006.01)
A61P 19/02 (2006.01) *A61P 43/00* (2006.01)
A61P 25/00 (2006.01) *A61K 45/06* (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/SG2021/050625

(22) International Filing Date:

15 October 2021 (15.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202010254Q 15 October 2020 (15.10.2020) SG
10202012817S 21 December 2020 (21.12.2020) SG

(71) Applicants: **ASLAN PHARMACEUTICALS PTE.**

LTD. [SG/SG]; 83 Clemenceau Avenue, #12-03 UE Square, Singapore 239920 (SG). **ALMIRALL, S.A.** [ES/ES]; Ronda del General Mitre, 151, E-08022 Barcelona (ES).

(72) Inventors: **MOORE, Robert**; 83 Clemenceau Avenue,

#12-03 UE Square, Singapore 239920 (SG). **ENDO, Isana**; 83 Clemenceau Avenue, #12-03 UE Square, Singapore 239920 (SG). **FIRTH, Carl**; 83 Clemenceau Avenue, #12-03 UE Square, Singapore 239920 (SG). **DOYLE, Stephen**; 83 Clemenceau Avenue, #12-03 UE Square, Singapore 239920 (SG). **GODESSART MARINA, Nuria**; Ronda del General Mitre, 151, E-08022 Barcelona (ES).

(74) Agent: **STERLING IP LIMITED**; 10 Anson Road,

#29-09 International Plaza, Singapore 079903 (SG).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: TREATMENT OF AUTOIMMUNE DISEASES WITH A DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITOR

(57) Abstract: A method of treating an autoimmune disease in a patient comprising administering a therapeutically effective amount of a DHODH inhibitor or a pharmaceutically acceptable salt thereof. Also provided are formulations or compositions suitable for treating autoimmune diseases.



WO 2022/081095 A1